BIOCAPTIVA Raises £1.58M To Transform Liquid Biopsy Sample Preparation

The round was led by Archangels, with participation from Old College Capital, BBI, Scottish Enterprise, and new investor EverQuest Capital Partners.

In addition, Biocaptiva appointed Alan Schafer as Chief Technology Officer (CTO) to support its technology and growth strategy.

The company plans to use the funding to boost R&D efforts, expand its product portfolio, and explore new applications.

Led by CEO Jeremy Wheeler, Biocaptiva is a biotechnology firm specializing in liquid biopsy technology. Spun out from the University of Edinburgh in 2021, Biocaptiva addresses a key limitation in cancer diagnostics: the low concentration of cell-free DNA (cfDNA) in standard blood samples.

Read Also - London-based Augur Raises $15M Funding In Seed Round

Its patented msX platform extracts DNA directly from whole blood without requiring centrifuges or additional reagents, enabling faster, more efficient, and potentially more sensitive diagnostic testing.

Biocaptiva is an award-winning Edinburgh biotechnology company revolutionizing liquid biopsy and nucleic acid extraction.

Using proprietary msX™ polymer technology, the company delivers high-quality, high-yield cell-free DNA, enabling breakthroughs in genetic disease detection, monitoring, and precision medicine for research and clinical applications.

About Biocaptiva

Founded in 2018 Biocaptiva is an Edinburgh-based biotechnology company transforming liquid biopsy and nucleic acid extraction. Its proprietary msX™ polymer technology delivers high-yield, high-quality cell-free DNA, supporting advancements in genetic disease detection, monitoring and precision medicine.